Debnath S, Zhou N, McLaughlin M, et al. PSMA-targeting imaging and theranostic agents-current status and future perspective. Int J Mol Sci. 2022;23(3):1158 (Epub 2022/02/16).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30(4):628–36 (Epub 2006/03/24).

Article  PubMed  Google Scholar 

Queisser A, Hagedorn SA, Braun M, Vogel W, Duensing S, Perner S. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Mod Pathol. 2015;28(1):138–45 (Epub 2014/06/14).

Article  PubMed  CAS  Google Scholar 

Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9(17):6357–62 (Epub 2003/12/26).

PubMed  CAS  Google Scholar 

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5 (Epub 1997/01/01).

PubMed  CAS  Google Scholar 

Lauri C, Chiurchioni L, Russo VM, Zannini L, Signore A. PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications? J Clin Med. 2022;11(21):6590 (Epub 2022/11/12).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. Nucl Med Biol. 2021;98–99:30–9 (Epub 2021/05/22).

Article  PubMed  Google Scholar 

Tan BF, Tan WCC, Wang FQ, et al. PSMA PET imaging and therapy in adenoid cystic carcinoma and other salivary gland cancers: a systematic review. Cancers (Basel). 2022;14(15):3585 (Epub 2022/07/28).

Article  PubMed  CAS  Google Scholar 

Di Villeneuve L, Souza IL, Tolentino FDS, Ferrarotto R, Schvartsman G. Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol. 2020;10:580141 (Epub 2020/11/17).

Article  PubMed  PubMed Central  Google Scholar 

Abghari-Gerst M, Armstrong WR, Nguyen K, et al. A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: results from a prospective multicenter study on 2,005 patients. J Nucl Med. 2022;63(4):567–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yadav MP, Ballal S, Sahoo RK, et al. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients. PLoS ONE. 2021;16(5):e0251375.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fallah J, Agrawal S, Gittleman H, et al. FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Konopnicki A, Zaliznyak M, Roy M, Jana B. The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials. Discov Oncol. 2024;15(1):791 (Epub 2024/12/18).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jalloul W, Ghizdovat V, Saviuc A, Jalloul D, Grierosu IC, Stefanescu C. Targeted alpha therapy: exploring the clinical insights into [225Ac]Ac-PSMA and its relevance compared with [177Lu]Lu-PSMA in advanced prostate cancer management. Pharmaceuticals (Basel). 2025;18(8):1215 (Epub 2025/08/30).

Article  PubMed  CAS  Google Scholar 

Zhang H, Koumna S, Pouliot F, Beauregard JM, Kolinsky M. PSMA theranostics: current landscape and future outlook. Cancers (Basel). 2021;13(16):4023 (Epub 2021/08/28).

Article  PubMed  CAS  Google Scholar 

Klein Nulent TJW, Valstar MH, de Keizer B, et al. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):478–86 (Epub 2018/03/11).

Article  PubMed  Google Scholar 

Nishida H, Kondo Y, Kusaba T, Kadowaki H, Daa T. Immunohistochemical reactivity of prostate-specific membrane antigen in salivary gland tumors. Head Neck Pathol. 2022;16(2):427–33 (Epub 2021/08/23).

Article  PubMed  Google Scholar 

Nishida H, Kusaba T, Kawamura K, Oyama Y, Daa T. Histopathological aspects of the prognostic factors for salivary gland cancers. Cancers (Basel). 2023;15(4):1236 (Epub 2023/02/26).

Article  PubMed  CAS  Google Scholar 

Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest. 2018;98(7):844–55.

Article  PubMed  Google Scholar 

Detre S, SaclaniJotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215(1):159–75 (Epub 2017/11/17).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35(9):919–27 (Epub 2020/04/14).

PubMed  Google Scholar 

Liu J, Kopeckova P, Buhler P, et al. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm. 2009;6(3):959–70 (Epub 2009/04/07).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rajasekaran SA, Anilkumar G, Oshima E, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4835–45 (Epub 2003/10/07).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sivrice ME, Yasan H, Kumbul YC, Ertunc O, Sayin S. The importance of prostate-specific membrane antigen expression in salivary gland tumors. Turk Arch Otorhinolaryngol. 2022;60(4):206–11.

Article  PubMed  Google Scholar 

Klein Nulent TJW, Valstar MH, Smit LA, et al. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer. 2020;20(1):519 (Epub 2020/06/07).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472–83 (Epub 2007/04/24).

Article  PubMed  CAS  Google Scholar 

Konig L, Hauswald H, Flechtenmacher C, et al. Uptake of prostate-specific membrane antigen (PSMA) in adenoid cystic carcinoma—is PSMA-PET-CT a helpful tool in radiation oncology? Clin Transl Radiat Oncol. 2017;7:79–82 (Epub 2018/03/30).

PubMed  PubMed Central  Google Scholar 

Katabi N. Oncocytoid salivary tumors: differential diagnosis and utility of newly described immunohistochemistry. Head Neck Pathol. 2024;18(1):20 (Epub 2024/03/19).

Article  PubMed  PubMed Central  Google Scholar 

Wright GL Jr., Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18–28.

Article  PubMed  Google Scholar 

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.